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Summary
Different genetic alterations may lead to type I inter-
feron (IFN)overproduction inhumansystemic lupuser-
ythematosus (SLE). The increased bioavailability of
type I IFN contributes to peripheral tolerance break-
down through the activation of immature myeloid
dendritic cells (mDCs). IFN-matured mDCs activate
autoreactive T cells. These cells, together with plasma-
cytoid DCs, help expand autoreactive B cells. IFN-
matured DCs also activate cytotoxic CD8+ T cells, pos-
sibly increasing apoptotic cell availability. The capture
of apoptotic cells bymDCs andof nucleic acid-contain-
ing immune complexes by plasmacytoid DCs and B
cells amplifies the autoimmune reaction leading to dis-
ease manifestations. Genetic alterations in lineages
other than B cells might explain other autoimmune
syndromes where type I IFNs appear to be involved.
Introduction
Interferon (IFN) was shown to act on cells of the immune
system more than 40 years ago. However, its role on the
pathogenesis of human disease, especially SLE, has
only recently been established. In 1979, interferon activ-
ity was found in the serum of patients suffering from sev-
eral autoimmune diseases (Hooks et al., 1979), a finding
that was subsequently confirmed mainly in SLE (Preble
et al., 1982). Further inference of the role of type I IFN
(refer to here as IFN-ab for both IFN-a and IFN-b) in
SLE came from the induction of autoimmunity during
IFN-ab therapy (Ronnblom et al., 1991) and the presence
of circulating inducers of IFN-ab in SLE blood. We pro-
posed in 2001 that a key pathogenic event in SLE might
be a break in peripheral tolerance mechanisms after ac-
tivation of myeloid dendritic cells (mDCs) in response to
an excess of IFN-ab (Blanco et al., 2001). This proposal
was based on three pieces of information: (1) the critical
role of immature mDCs in the maintenance of peripheral
tolerance, as opposed to mature mDCs that induce
antigen-specific immunity (Banchereau et al., 2000;
Steinman et al., 2003), (2) the remarkable capacity of
plasmacytoid DCs (pDCs) to secrete large amounts of
IFN-ab upon exposure to viruses (Siegal et al., 1999),
and (3) the ability of IFN-ab to activate immature mDCs
(Blanco et al., 2001).
Systemic Lupus Erythematosus
There is a spectrum of human lupus ranging from solely
skin involvement to systemic disease, the common
*Correspondence: jacquesb@baylorhealth.edu (J.B.); virginip@
baylorhealth.edu (V.P.)denominator being tissue damage resulting from the
deposits of immune complexes (IC) that fix complement.
Systemic disease is characterized by a relapsing and re-
mitting course with flares of high morbidity. SLE patients
are predominantly women who present with chronic
nonspecific symptoms such as fever, weight loss, and
fatigue often associated to lymphadenopathy and espe-
cially lymphopenia. Some patients may present with se-
vere acute illness characterized by seizures, psychosis,
renal failure, profound anemia, pulmonary hemorrhage,
or sepsis. Confirming the diagnosis of SLE requires the
fulfillment of 4 out of 11 criteria, one of those being the
presence of anti-nuclear antibodies (ANA), which are de-
tected in >95% of patients. Loss of tolerance to nuclear
antigens is restricted to chromatin components (such as
dsDNA, histones, and nucleosomes) and U-rich ribonu-
cleoproteins (such as RNP and Sm), which are Toll-like
receptor 9 (TLR9) and TLR7 ligands, respectively (Martin
and Elkon, 2005). Antibodies against phospholipids
(complexed to b2-glycoprotein) exposed on the surface
of dying cells are also frequently detected in SLE pa-
tients and correlate with the development of thrombo-
embolic complications. Autoantibodies directed to
cell-surface molecules, especially those expressed on
cells of hemopoietic origin, cause hemolytic anemia,
neutropenia, and thrombocytopenia. Antibodies against
antigens expressed in target organs like the kidney (glo-
merular extracts) are also found in patients with severe
kidney disease (Li et al., 2005). In addition to the direct
damage caused by cellular and/or tissue antigen-anti-
body interactions, many lupus symptoms result from in-
direct damage through the deposition of IC on tissues
(i.e., nephritis, arthritis, and vasculitis).
Genetic defects in molecules involved in the removal
of anti-DNA-nucleosome complexes (i.e., complement
proteins, C-reactive protein, etc.) are among the stron-
gest genetic factors predisposing to SLE. However,
most SLE patients do not have mutations in this partic-
ular set of genes. Multicase family-based genome scans
with microsatellite markers have identified more than 12
candidate genes (those that encode FcgR, CD2, CR2,
FCRL3, CD45, HF1, Ro, PARP, PDCD1, HLA, TNF, C4)
distributed along 6 chromosomes (Alarcon-Riquelme,
2005). Genetic association studies with single-nucleo-
tide polymorphisms have confirmed the involvement of
genes that encode FcgR and complement while disclos-
ing other novel candidates. A common haplotype of in-
terferon regulatory factor 5 (IRF5), a transcription factor
expressed in pDCs and B cells, is associated with
increased risk of SLE. IRF5 acts downstream of the
TLR-MyD88 signaling pathway in the induction of proin-
flammatory cytokines (Takaoka et al., 2005). The associ-
ation of SLE with IRF5 polymorphisms giving rise to
unique IRF-5 isoforms has been confirmed across differ-
ent ethnic backgrounds (Graham et al., 2006).
IFN therapy in cancer and viral infections induces
autoantibody formation in 4%–19% of patients and a
variety of SLE symptoms have been reported in 0.15%–
0.7% of them. SLE is a remitting disease characterized
by flares often associated to viral infections, which
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384might trigger unabated production of IFN-ab. Even
though the effects of IFN-ab may explain many SLE fea-
tures, not every SLE patient displays elevated serum
IFN-ab. However, peripheral blood mononuclear cells
(PBMCs) from all active pediatric SLE patients upregu-
late IFN-induced genes as defined in vitro by culturing
healthy PBMCs with IFN-ab (Bennett et al., 2003). The
expression of a subset of these IFN- as well as neutro-
phil-related genes correlates better with disease activity
than titers of dsDNA antibodies. Furthermore, treating
SLE patients with high-dose intravenous steroids, which
induce clinical remission, abrogates the IFN-ab signa-
ture in PBMCs (Bennett et al., 2003). This effect might re-
sult from pDC depletion (Shodell et al., 2003), supporting
the role of pDCs and IFN-ab in disease pathogenesis.
Leukocytes from most adult SLE patients also display
a remarkable IFN signature that correlates with disease
severity (Baechler et al., 2003). The expression of the
same spectrum of IFN-regulated genes is induced by
culturing healthy blood cells with SLE plasma samples,
and this activity is >90% inhibited by IFN-a antibody,
but not by IFN-b or IFN-g antibodies (Hua et al., 2006).
Systemic Lupus Erythematosus Animal Models
Several murine lupus models exist, though none of them
appears to fully reproduce the human disease. They can
be divided into spontaneous, congenic, and engineered
models (Liu and Mohan, 2006). The best known sponta-
neous models arise on New Zealand Black (NZB), New
Zealand White (NZW), MRL, BXSB, and SWR back-
grounds. Hybrids of some of these background strains,
like the NZB/W F1, NZM2410, and the SWR/NZB F1
develop ANA, glomerulonephritis, and other features of
human disease. The lpr (Fas) or gld (FasL) mutations
on the MRL background give rise to mice with features
of human lupus. Yet, the massive degree of lymphopro-
liferation that occurs in these mice is not found in hu-
mans. Additionally, although MRL-lpr/lpr mice sponta-
neously develop arthritis, it displays more features of
rheumatoid arthritis than of the arthropathy seen in
human SLE. Conversely, humans carrying mutations in
the Fas/FasL genes do not develop SLE. The Yaa muta-
tion, which accelerates disease on the BXSB back-
ground, is due to a translocation of the TLR7 gene into
the Y chromosome, explaining the predominantly male
predisposition to disease in this particular model
(Pisitkun et al., 2006; Subramanian et al., 2006), which
is at striking difference with the 9:1 female to male ratio
in human SLE.
Congenic mice bearing individual predisposing loci on
lupus-resistant strains have been generated. The best-
studied models bear the NZM2410-derived Sle1, Sle2,
and Sle3/5 intervals on the B6 background (Liu and Mo-
han, 2006). These models underscore the importance of
epistatic interactions among different loci. Sle1, for
example, is a genetic interval responsible for breaking
B cell tolerance to chromatin. However, this interval
does not lead to disease manifestations unless in epis-
tasis with Sle2 (B cell hyperactivity), Sle3/5 (APC hyper-
activity), Yaa (TLR7 duplication), or lpr (Fas mutation).
Many lupus-like syndromes arise in mice deficient in
single genes. They fall into two main categories: clear-
ance of apoptotic cells and lymphocyte activation and
survival. Genes encoding proteins that fall within the first(C1q, C2, C4, and Dnase I) and second (CD45, CTLA-4,
PD1, and FcgRIIb) groups are also candidate suscepti-
bility genes in humans according to linkage and/or asso-
ciation studies (Alarcon-Riquelme, 2005).
Studies in lupus-prone mice have confirmed the criti-
cal role of IFN-ab in SLE pathogenesis. In vivo delivery
of IFN-ab to preautoimmune NZB/W F1 mice rapidly
results in severe SLE. dsDNA antibodies appear as early
as 10 days after initiation of IFN-a treatment, demon-
strating a critical role for IFN-a in the selection and ex-
pansion of autoreactive clones. Proteinuria and glomer-
ulonephritis-induced death occurred in all treated mice
at 9 and 18 weeks, respectively, a time when untreated
mice did not show any sign of disease (Mathian et al.,
2005). Conversely, the cross of both NZB and B6 lpr/
lpr mice with a type I IFN receptor-deficient strain sub-
stantially decreases morbidity and prolongs the survival
of these animals (Braun et al., 2003; Santiago-Raber
et al., 2003). As opposed to the NZB/W model, IFN-g
but not IFN-ab seems to mediate disease in the MRLlpr
mice. Indeed, deficiency of the IFN-g or the IFN-g recep-
tor genes leads to a delay in both the onset of disease
and the severity of glomerulonephritis (Balomenos
et al., 1998), whereas these symptoms are enhanced
when the mice are rendered deficient in the type I IFN re-
ceptor (Hron and Peng, 2004). These data, together with
the expression of a strong IFN-g gene signature in the
spleen (Liu et al., 2006), support the role IFN-g in the
lpr model. IFN-g, however, has not yet been linked to
any human autoimmune disease.
Cellular Aspects of SLE: Dendritic Cells
DCs are the initiators and regulators of immune re-
sponses. The recognition that DCs control immunity
and tolerance (Hawiger et al., 2001; Steinman et al.,
2003) led to the hypothesis that SLE may be driven by
unabated DC activation. Classically, two main DC differ-
entiation pathways are recognized (Banchereau et al.,
2000): myeloid DCs (mDCs) and plasmacytoid DCs
(pDCs) (Liu, 2005).
Tissue-resident mDCs that encounter microbes at
mucosal surfaces or at sites of tissue damage migrate
to the lymph node via afferent lymphatics. Importantly,
mDC express receptors, such as TLRs, nucleotide bind-
ing oligomerization domain (NOD) proteins, and lectins,
to sense these pathogens. Mouse mDCs express TLR7
and TLR9, whereas human mDCs lack TLR9 but express
TLR7 upon exposure to IFN-ab (Mohty et al., 2003).
mDCs can also be activated by ICs through the activat-
ing FcgRIIa (Boruchov et al., 2005; Dhodapkar et al.,
2005).
pDCs circulate in the blood and lymphoid organs.
Upon viral exposure, these cells secrete large amounts
of IFN-ab as well as other cytokines (Liu, 2005). They
also differentiate into cells with DC morphology and
function (Grouard et al., 1997). Both mouse and human
pDCs express TLR7 and TLR9. Chromatin-containing
and snRNPs-containing ICs are internalized by pDCs
via FcgRIIa and reach the endosomal compartment
where they activate TLR9 and TLR7, respectively, lead-
ing to secretion of cytokines including IFN-ab (Figure 1;
Barrat et al., 2005; Bave et al., 2003; Boule et al., 2004;
Honda et al., 2005; Means et al., 2005). The classic lupus
autoantigens snRNPs can also be directly internalized
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(Vollmer et al., 2005).
Autoreactive T cells that are not purged in the thymus
are controlled in the periphery by immature DCs (periph-
eral tolerance). In the steady state, immature mDCs
capture apoptotic cells and migrate, without maturing,
to the draining lymph node. There, they present self-pep-
tide-MHC complexes, in the absence of costimulation
signals, to the circulating naive autoreactive T cells, re-
sulting in their anergy or deletion. Immature DCs may
also control peripheral tolerance through induction and
maintenance of regulatory T cells. Such tolerance mech-
anisms prevent or reduce the development of auto-
immunity when dying cells are generated and processed
at the time of infection. It can thus be easily imagined that
‘‘inappropriate’’ activation of what should otherwise be
an immature, tolerogenic DC may lead to the break of pe-
ripheral tolerance and launch immunity to self-antigens.
Monocytes represent a major source of precursor
DCs under inflammatory conditions, and a combination
of IFN-ab and GM-CSF drives them to differentiate into
DCs. Indeed, blood monocytes from SLE patients be-
have like mDCs, and exposure of normal monocytes to
SLE serum results in the generation of DCs (Blanco
et al., 2001). Thus, SLE blood, through its IFN-ab con-
tent, represents a DC-inducing environment. Unabated
DC maturation could lead to the activation and expan-
sion of autoreactive T cells, thus explaining many of
the features of the disease (Banchereau et al., 2004).
Figure 1. Immune Complexes Activate pDCs and B Cells
Immune complexes are formed when autoantibodies are engaged
with either (1) chromatin whose DNA can interact with TLR9 inside
pDC and B cell endosomes or (2) ribonucleoproteins whose RNA
can interact with TLR7 also inside pDC and B cell endosomes.
TLR signaling in pDC results in the secretion of IFN-ab and IL-6.
The combined triggering of the autoreactive BCR and TLR results
in autoreactive B cell proliferation; IFN-ab induce their differentiation
into plasmablasts and IL6 induces their differentiation into autoanti-
body-secreting plasma cells.DCs generated in the presence of SLE sera also drive
the differentiation of CD8+ T cells toward fully active cy-
totoxic effector T lymphocytes able to generate nucleo-
somes (Blanco et al., 2005) and granzyme B-dependent
autoantigens (Casciola-Rosen et al., 1999). These auto-
antigens could be captured and presented by mDCs,
thereby further broadening the autoimmune process. In-
deed, administration of DCs loaded with apoptotic cells
triggers autoimmune responses in mice, although clini-
cal autoimmunity develops only in genetically suscepti-
ble recipients (Bondanza et al., 2003).
pDC numbers are reduced in SLE blood (Blanco et al.,
2001), but these cells massively infiltrate inflamed lupus
skin (Farkas et al., 2001). The decrease in SLE blood
pDCs might thus result from their accelerated migration
to inflammation sites, as demonstrated in allergen-chal-
lenged nasal mucosa (Jahnsen et al., 2000).
Cellular Aspects of SLE: T Cells
Alterations in SLE T cells may originate from defects in T
cell subset representation, activation, and senescence
(Kyttaris and Tsokos, 2004). T and B cell lymphopenia
are common in SLE patients. This defect may be due
to an excess of IFN-ab, as indicated by the fact that ad-
ministration of IFN-ab in neonatal mice results in lym-
phopenia (Lin et al., 1998). SLE CD4+ T cells express
high amounts of CCR4, which might drive their migration
into kidneys (Yamada et al., 2002). Increased expression
of perforin by SLE CD4+ T cells might also contribute to
increased cytotoxic properties. Indeed, our preliminary
observations suggest that IFN-ab-stimulated DCs might
favor the generation of these cells.
Very little is known about the status of regulatory T
cells in SLE, though IFN-a strongly enhances IL-10-
induced differentiation of functional CD4+ T regulatory
cells (Tr1) (IL-10+, IFN-g+, IL-22/lo, IL-42) (Levings
et al., 2001). This Tr1 population, however, has not
been studied in SLE patients. Likewise, alterations of
the follicular B helper T cell population (TFh), which plays
a crucial role in high-affinity antibody responses and B
cell memory within germinal centers, may occur in
SLE. The TFh cells are expanded in two murine lupus-
like models: the sanroque mice carrying a mutated ubiq-
uitin ligase (roquin) gene (Vinuesa et al., 2005) and the
B6.Sle1.yaa mice carrying a polymorphic cluster encod-
ing SLAM and CD2 in addition to a duplication in TLR7
(Subramanian et al., 2006). No information is available
on the status of the TFh cells in human SLE.
Despite the overall lymphopenia, CD8+ T cells are in-
creased in frequency, particularly in patients with severe
lupus nephritis (Matsushita et al., 2000). Additionally, an
increased proportion of SLE CD8+ T cells express HLA-
DR, a marker of activation (Viallard et al., 2001). The
CD8+ T cell compartment is remarkably skewed with a
prominent depletion of the naive repertoire (CCR7+
CD45RO2) to the benefit of the central memory (CM)
T cells (CCR7+CD45RO+) that spontaneously secrete
IL-4 and IL-5 (Sen et al., 2004). SLE patients with disease
flares also display higher proportions of perforin- and/or
granzyme B-positive lymphocytes with a differentiated
effector phenotype (CCR72 and CD45RA+) (Blanco
et al., 2005). Interestingly, administration of IFN-ab to
metastatic melanoma patients also results in an in-
crease of circulating terminally differentiated effectors
Immunity
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serum promote the differentiation of CD8+ effector T
cells, which can kill target cells and generate nucleo-
somes and SLE autoantigens in a granzyme-dependent
manner (Blanco et al., 2005).
In mice, IFN-ab prevents activated T cell death during
inflammatory responses (Marrack et al., 1999), and IFN
signaling in CD8+ T cells is critical for the generation of
effector and memory cells in response to viral infections
(Figure 2; Kolumam et al., 2005). IFN-ab also directly
stimulates CD4+ T cells to enhance antigen-specific B
cell responses (Le Bon et al., 2006b) and prolongs the
proliferation and expansion of antigen-specific CD8+
T cells during crosspriming (Le Bon et al., 2006a).
Cellular Aspects of SLE: B Cells
The key role that B cells play in the pathogenesis of SLE
is supported by the clinical improvement of patients
treated with the B cell-depleting CD20 antibody (rituxi-
mab) (Isenberg, 2006). Indeed, profound alterations in
blood B cell compartments have been described in
SLE. Conventional naive and memory B cell numbers
are decreased whereas CD38+ B cells, which include oli-
goclonal plasma cell precursors (PCPs), are expanded.
The high expression of CD38 on B cells might actually
be due to IFN-ab exposure (Jego et al., 2003). PCPs dis-
play a phenotype similar to that of PCPs found in the
blood during secondary immune responses, including
isotype-switched and mutated Ig genes (Arce et al.,
2001). Whether these SLE PCPs will become short-lived
or long-lived plasma cells is not clear yet. Studies in
mice suggest that they may be only short lived (our
unpublished data).
Large numbers of developing B cells in the bone mar-
row and recent emigrants in the blood express self-re-
active B cell receptors (BCRs). They represent, however,
only 5%–20% of healthy naive blood B cells, but as
many as 25%–50% of the SLE blood naive B cells, sug-
gesting that there is an alteration of a tolerance check
point in these patients (Yurasov et al., 2005). Further ev-
idence for altered B cell tolerance checkpoints in SLE
comes from the analysis of B cells expressing the
VH4-34 gene, which encodes autoantibodies of different
specificities. In healthy individuals, VH4-34+ B cells are
excluded during the early stages of the germinal center
(GC) reaction, thus representing a second tolerance
checkpoint in the life of a B cell. In SLE, but not in rheu-
matoid arthritis (RA), patients, VH4-34+ cells progress
through this checkpoint, participate in GC reactions,
and are expanded within the post-GC IgG memory and
plasma cell compartments (Cappione et al., 2005). The
gene(s) responsible for the control of human B cell
tolerance checkpoints in SLE patients are not known.
However, in the Sle1z/Sle1bz mouse, an SLE suscepti-
bility locus on chromosome 1 associated with produc-
tion of chromatin antibodies has been shown to impair
B cell anergy, receptor revision, and deletion. The
Ly108.1 isoform of the Ly108 gene, a member of the
SLAM costimulatory family, influences the ability of im-
mature B cells to undergo deletion and RAG reexpres-
sion and represents a potential controller of tolerance
checkpoints in this model (Kumar et al., 2006).
Through their effect on B cells, IFN-ab directly enhance
primary antibody responses to soluble proteins andinduce the production of all subclasses of IgG in mice
(Le Bon et al., 2006b). Furthermore, IFN-ab promotes the
differentiation of mDCs that can directly act on the growth
and differentiation of B cells (Dubois et al., 1997; Garcia De
Vinuesaet al., 1999). mDCstrigger B cell growth and differ-
entiation throughIL-12andIL-6 (Duboiset al., 1998)as well
as B cell-activating factor (BAFF) (Litinskiy et al., 2002).
BAFF is induced by IFN-ab and contributes to the survival
of peripheral B cells, inlcuding those expressing autoreac-
tive B cell receptors (Thien et al., 2004). Virus-stimulated
pDCs can induce the maturation of activated B cells into
plasma cells. First, IFN-ab promotes the differentiation of
activated B cells into plasmablasts (Figure 2), and then
IL-6 permits plasmablasts to become antibody-secreting
plasma cells (Jego et al., 2003).
The contribution of IC and TLR signaling to the gener-
ation of autoantibodies characteristic of SLE has at-
tracted numerous studies in mice, but less is known in
humans (Figure 1). In vitro, chromatin-containing IC ac-
tivate transgenic autoreactive B cells via sequential en-
gagement of the B cell antigen receptor (BCR) and TLR9
Figure 2. The Four Immune Targets of IFN
Under steady state, immature myeloid DCs capture apoptotic bod-
ies and present their autoantigens, without costimulatory mole-
cules, to autoreactive lymphocytes, which are then deleted (left
arm). Upon viral infection, SLE pDCs produce IFN-ab in a sustained
fashion. IFN activates myeloid DCs, which now present nucleic acid-
containing autoantigens from apoptotic bodies. The high expression
of costimulatory molecules triggers the expansion and differentia-
tion of autoreactive lymphocytes. Autoreactive CD4+ T cells provide
help to differentiate autoreactive CD8+ T cells and B cells into autor-
eactive effectors. Autoreactive CTLs contribute to tissue damage
and apoptotic body overload. Autoreactive plasma cells secrete au-
toantibodies, which will generate nucleic acid-containing immune
complexes. These can activate pDCs to make more IFN-ab, and
autoreactive B cells to proliferate and differentiate in response to
pDC-derived IFN and IL-6. These activated B cells might also
engage into a germinal center reaction that will increase the affinity
of autoreactive antibodies. Thus, low-affinity nonpathogenic might
become high-affinity pathogenic autoantibodies.
Review
387(Leadbetter et al., 2002). In vivo, TLR9 contributes to the
development of dsDNA antibodies, as shown by the fact
that lupus-prone (Fas-deficient) mice that lack TLR9 on
the mixed MRL-B6-129 background fail to generate
these antibodies. Yet, the production of cardiolipin and
RNA-reactive antibodies and the development of ne-
phritis are not affected in these mice (Christensen
et al., 2005). On a different mouse background (B6
mice lacking the inhibitory FcgRIIb), TLR9 signaling is
required for anti-DNA polyreactive IgM+ B cells that
have escaped central tolerance to switch to pathogenic
isotypes (Ehlers et al., 2006). Yet, in a different mouse lu-
pus-like model, the pure MRL/lpr, TLR9 seems to deliver
protective signals, because TLR9-deficient MRL/lpr
mice develop more autoantibodies and severe lupus-
like disease (Wu and Peng, 2006). As discussed earlier,
this model seems to be mediated by IFN-g and not
IFN-ab: the absence of type I IFN receptor worsens dis-
ease in these mice (Hron and Peng, 2004), which is at
variance with the NZB model (Santiago-Raber et al.,
2003).
Conclusions drawn from lupus-like models should
therefore be extrapolated to humans only with caution.
First, the expression of TLR9 on immune cells differs
markedly in mice and humans. Second, the various mu-
rine lupus-like models may not faithfully reproduce the
human disease. For example, mutations in Fas-FasL,
which are the hallmark of the MRL, lpr, or gld models ex-
tensively studied as surrogates to human SLE, do not
cause this disease in humans. Instead, these mutations
give rise to a unique syndrome characterized by lym-
phoproliferation and autoimmunity that is easy to differ-
entiate from SLE.
TLR7 signaling also seems to contribute to SLE-like
syndrome in mice. As shown for pDCs, immune com-
plexes containing RNA and RNA-associated autoanti-
gens activate autoreactive B cells in vitro (Lau et al.,
2005). In vivo, FcgRIIb-deficient mice develop enhanced
autoimmunity when crossed to the Y-linked autoim-
mune accelerator (Yaa) locus, which harbors a duplica-
tion in the TLR7 gene (Pisitkun et al., 2006). Finally, injec-
tion of the TLR7 ligand Imiquimod increases serum
amounts of IL-12p70, IFN-a, and IL-6 and aggravates
lupus nephritis in MRL/lpr mice (Pawar et al., 2006). Nat-
urally occurring differences in expression of the TLR7
gene, as well as environmental factors that induce
TLR7 expression (i.e., IFN-ab [Mohty et al., 2003]) and /
or TLR7 responses, could therefore result in increased
pDC and B cell responses to RNA-containing self anti-
gens and contribute to human SLE pathogenesis as
well.
Cellular Aspects of SLE: Neutrophils
Microarray analysis of SLE blood reveals a striking
signature of neutrophil-specific transcripts whose ex-
pression correlates with disease activity and with the
presence of lupus nephritis (Bennett et al., 2003, and
our own unpublished data). Interestingly, the presence
of neutrophils on lupus kidney biopsies has been long
considered a marker of active nephritis, and these cells
may be also be associated to vasculitis in SLE. Neutro-
phils could thus contribute to end-organ damage
through the release of proteases, possibly after IC trig-
gering. Furthermore, immature neutrophils may be dy-ing outside their natural microenvironment and thus
may represent a major source of nuclear autoantigens.
IFN-ab might be responsible for the mobilization of neu-
trophils, as indicated by the fact that it induces G-CSF
secretion (Fukuda et al., 2000). G-CSF-stimulated neu-
trophils, which release BAFF as efficiently as activated
monocytes or DCs (Scapini et al., 2003), might also
play an unsuspected role in the regulation of B cell
homeostasis. Neutrophils may also contribute to DC
activation through several mechanisms, including the
production of proinflammatory cytokines, chemokines,
and defensins (Yang et al., 1999), and interactions be-
tween the integrin Mac-1 and DC-SIGN (van Gisbergen
et al., 2005). Accumulation of neutrophils has been de-
scribed in the spleen of B6.yaa.Sle1 mice (Subramanian
et al., 2006) and of NZB/W F1 mice after IFN-a adminis-
tration (our unpublished data).
Interferon in SLE
We have proposed a unified model where pDCs are con-
sidered to be the main producers of IFN-ab in SLE. In-
deed, pDCs accumulate in the skin at the site of SLE
rashes where they might produce the IFN-ab in excess.
The disease might depend on an excessive production
of pDCs because of Flt3L, which is found increased in
SLE serum (Gill et al., 2002). Upon viral infection, healthy
pDCs secrete IFN for a few hours, and then they secrete
other cytokines including TNF, which shuts down auto-
crine IFN-ab production. Genetic alterations in SLE
might prevent the shutdown of IFN production, as illus-
trated by the SLE-like syndrome of SOCS-deficient mice
(Hanada et al., 2003). Second, there might be alterations
in the expression of molecules that can control IFN se-
cretion. For example, the increased amounts of soluble
TNF receptors in SLE serum (Gill et al., 2002) might con-
tribute to sustained IFN-ab production by blocking TNF
(Palucka et al., 2005). Alternatively, the presence of im-
mune complexes containing either RNA or DNA may
sustain IFN production by pDCs through triggering of
TLR7 and TLR9, respectively (Barrat et al., 2005; Lau
et al., 2005; Vollmer et al., 2005). Other cell types may
also contribute to the overall increased bioavailability
of IFN-ab in SLE. For example, IFN-ab triggers TLR7
expression on monocytes and DCs, which can then
be induced to produce IFN-ab in response to TLR7 ago-
nists (Mohty et al., 2003), such as virus-derived single-
stranded RNA.
Under steady state, immature mDCs capture apopto-
tic bodies and present their autoantigens without costi-
mulatory molecules to autoreactive lymphocytes, which
are then deleted (see Figure 2). Upon viral infection, SLE
pDCs produce IFN-ab in a sustained fashion. IFN-ab ac-
tivates mDCs, which could then present nucleic acid-
containing autoantigens from apoptotic bodies. The
autoantigens might be presented on MHC class I and
class II molecules. The high density of costimulatory
molecules allows these mDCs to trigger the expansion
and differentiation of lymphocytes into autoreactive
CTLs and autoreactive helper T cells. The activated
mDCs are also likely to present autoantigens to B cells
(Macpherson and Uhr, 2004; Qi et al., 2006; Wykes
et al., 1998), leading to B cell maturation and isotype
switch (Caux et al., 1997). Activated mDCs and autor-
eactive helper T cells will induce autoreactive plasma
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cleic acid-containing IC. Activated pDCs might contrib-
ute to plasma cell generation as well, because they
induce the differentiation of proliferating B cells into
plasma cells through IFN and IL-6 (Jego et al., 2003).
One unresolved issue is the distinction between autor-
eactive B cell priming and reactivation of autoreactive
memory B cells. The priming may be dependent on
mDCs, whereas the memory activation may be depen-
dent on mature pDCs (our own unpublished data). The
role of affinity maturation also remains to be under-
stood. In this respect, the number and size of germinal
centers, which are the sites of somatic mutation, B cell
selection, and isotype switching, dramatically increase
in the lymphoid organs of NZB/W mice treated with
IFN-a (our unpublished data). These may represent sites
where autoreactive antibodies increase their affinity,
transforming a low-affinity, nonpathogenic autoanti-
body into a high-affinity pathogenic one.
As described for SLE-like murine models, SLE pa-
tients may display genetically imprinted alterations in B
cell tolerance checkpoints that would allow the survival
of autoreactive clones into the peripheral compartment.
IFN-ab and/or IFN-ab-stimulated DCs might contribute
to the survival of these clones into autoantibody-secret-
ing plasma cells. Indeed, healthy relatives of SLE pa-
tients often display ANA. Furthermore, only a fraction
of patients receiving IFN-a therapy develop ANA. Simi-
larly, B6.Sle1 congenic mice display intrinsic B cell alter-
ations that lead to the development of chromatin anti-
bodies in the absence of T cell help. In spite of the high
autoantibody titers, these mice do not develop further
SLE manifestations (Liu and Mohan, 2006). In humans,
clinical SLE is preceded by the progressive accumula-
tion of autoantibody specificities up to 9 yr before diag-
nosis. Ro, La, and phospholipid antibodies appear first,
followed by dsDNA antibodies and then Sm and nuclear
ribonucleoprotein antibodies (Arbuckle et al., 2003).
Thus, as it has been observed in lupus-prone mice, the
presence of SLE-specific antibodies is not enough to
cause overt disease. Other factors, like IFN-ab, may be
necessary to produce the amount and/or quality of auto-
antibodies that will sustain the formation of IC able to
activate B cells and pDCs.
Other Autoimmune Syndromes with a Potential Role
for Type 1 IFN
The therapeutic use of IFN-ab to treat cancer and hepa-
titis patients is associated with the induction of autoim-
munity other than SLE. Although thyroiditis is the most
common autoimmune manifestation, diabetes and auto-
immune dermatitis have also been described. Indeed,
elevated expression of IFN-a was found in the pancreas
of recently diagnosed insulin-dependent diabetes melli-
tus (IDDM) patients (Huang et al., 1995). In dermatomyo-
sitis, an autoimmune disease targeting the skin and
proximal muscle groups, muscle biopsies reveal infiltra-
tion with pDCs as well as IFN-ab-inducible gene and
protein expression (Greenberg et al., 2005; Tezak
et al., 2002). Sjogren’s syndrome (SS), an autoimmune
disease affecting mainly salivary and lacrimal glands,
also seems to be associated with alterations in IFN-ab
production, as shown by pDCs infiltrating SS salivary
gland biopsies (Gottenberg et al., 2006). IFN-induciblegenes are overexpressed in minor salivary glands and
ocular epithelial cells, and ICs from the serum of SS
patients activate pDCs to secrete IFN-ab (Bave et al.,
2005).
Although psoriasis patients are efficiently treated with
TNF antagonists, several observations suggest the po-
tential involvement of IFN-ab in the pathogenesis of
the disease. The induction of psoriasis after injection
of recombinant IFN-a (Funk et al., 1991), the presence
of an activated IFN-ab signaling pathway in keratino-
cytes (van der Fits et al., 2004), and the development
of psoriasiform inflammation in IRF-2-deficient mice
(Hida et al., 2000) all point to the involvement of IFN-
ab. A functional role of IFN-ab in the initiation of psoria-
sis has recently been demonstrated. Although IFN-ab is
not elevated in fully established psoriatic plaques, it is
produced at early stages. Indeed, pDCs infiltrate the
skin of psoriatic patients and become activated to pro-
duce IFN-ab early during disease formation. In a xeno-
graft model of human psoriasis, blocking IFN-a signaling
or inhibiting the ability of pDCs to produce IFN-ab
prevented the T cell-dependent disease development
(Nestle et al., 2005). Thus, the initial stages of psoriasis
development might be IFN-ab dependent whereas the
late stages are TNF dependent. TNF may also play
a role in late-stage end organ damage in SLE patients.
Indeed, treatment with TNF blockers led to clinical im-
provement of arthritis and decreased proteinuria in an
open label study including six SLE patients. As ex-
pected, autoantibodies to dsDNA and cardiolipin in-
creased in the majority of them (Aringer et al., 2004).
Crossregulation of TNF and IFN-ab in Autoimmune
Diseases
TNF has been the first cytokine whose dysregulation
was shown to be associated to an autoimmune disease.
Indeed, the clinical success of TNF antagonists demon-
strate that TNF plays a critical role in the pathogenesis of
diseases such as rheumatoid arthritis and psoriasis
(Feldmann and Maini, 2001). However, these antago-
nists may lead to clinical complications, such as reacti-
vation of tuberculosis and induction of reversible SLE.
Anti-TNF therapy may also worsen the clinical symp-
toms of established SLE. In fact, TNF antagonists
enhance the production of IFN-ab by pDCs exposed in
vitro to viruses whereas TNF inhibits it, suggesting that
the secretion of TNF by pDCs represents an endoge-
nous mechanism to control IFN production. Treatment
of patients suffering from systemic onset juvenile idio-
pathic arthritis with anti-TNF induces overexpression
of IFN-ab-regulated genes in blood leukocytes (Palucka
et al., 2005). The high amounts of soluble TNF receptors
found in SLE patients (Gill et al., 2002) may block endog-
enous TNF. TNF-mediated downregulation of the IFN-ab
pathway could also explain earlier observations in the
mouse lupus model NZB/W, which bear a genetic defi-
ciency in TNF. Consequently, these mice benefit from
replacement therapy with recombinant TNF (Jacob
and McDevitt, 1988).
Conversely, there is evidence that IFN-ab may regu-
late TNF. For example, TNF is implicated in the patho-
genesis of multiple sclerosis. In humans, IFN-b inhibits
in vitro TNF production by microglia, which might par-
tially explain the beneficial effect of IFN-b therapy in
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389Figure 3. The Compass of Immunity and
Immunopathology
Top: In an extension of the Th1-Th2 para-
digm, immunity is viewed as a dynamic sys-
tem driven by two sets of vectors, i.e., TNF
and IFN-ab, IL-4 and IFN-g. The sum of the
vectors yields an equilibrium point, which
allows protective immunity when vectors
are equal. When one of the vectors prevails
beyond a certain threshold, the equilibrium
point moves into a zone of immunopathology.
When the IFN-ab vector prevails, then IFN-
ab-mediated autoimmunity, i.e., lupus, oc-
curs. The prevalence of one vector may be
due to its absolute strengthening because
of the increased production of the cytokine
or its relative strengthening because of weak-
ening of the counteracting cytokine. Bottom:
The cytokine vectors yield distinct DC sub-
sets that might lead to distinct immunopa-
thologies. Immature DCs exposed to IFN-ab
or TNF will yield distinct DC subsets that will
uniquely polarize naive T cells though the
expression of different cytokines and costi-
mulatory molecules. It is also proposed that
the different DCs, through the expression of
distinct proteolytic enzymes, might generate
a different repertoire of peptides that will
select a different lymphocytic repertoire.
IFN-DCs may thus present chromatin/RNP-
derived peptides while TNF-DCs may present
IgFc.this disease (Hofman et al., 1989). Furthermore, PBMCs
from healthy volunteers injected with IFN-b show mark-
edly decreased secretion of TNF and lymphotoxin as
compared to placebo-treated volunteers (Rothuizen
et al., 1999). We have proposed an extension of the
Th1-Th2 (inflammation-allergy) paradigm (Mosmann
and Coffman, 1989), which integrates autoimmune re-
sponses (Figure 3). Here immunity is viewed as a dy-
namic system driven by two sets of opposite vectors,
i.e., TNF-IFN-ab and IL-4-IFN-g. The sum of the vectors
yields an equilibrium point, which allows protective im-
munity when vectors are equal. This dynamic system
can accommodate the prevalence of either vector to
a certain extent. However, when one of the vectors pre-
vails beyond a certain threshold, the equilibrium point
moves into a zone of immunopathology, such as autoim-
munity, allergy, or inflammation. Thus, when the TNF
vector prevails, TNF-mediated autoimmunity such as ar-
thritis will occur. When the IFN-a/b vector prevails, IFN
autoimmunity such as SLE will occur. This might be
due to increased bioavailability of one cytokine or de-
creased bioavailability of the other one. The unabated
production of a given cytokine will affect the cells of
the immune system and most particularly DCs. Thus,
IFN-stimulated DC will polarize naive T cells differently
than TNF-stimulated DCs.
Conclusions
In summary, just like many roads lead to Rome, we con-
tend that many genetic alterations might lead to the
sustained overproduction of IFN-ab in human SLE. The
resulting increased bioavailability of IFN-ab induces
the activation of immature mDCs that control peripheral
tolerance by deleting autoreactive lymphocytes. IFN-
matured DCs activate and expand autoreactive T cells,both helping autoreactive B cell development. In addi-
tion to its indirect effect through DCs, IFN-ab also
directly allows the expansion and survival of CD4+ and
CD8+ T cells as well as the differentiation of B cells
into plasma cells. The increased frequency of autoreac-
tive B cells depends on a second set of genetic alter-
ations targeting B cell tolerance checkpoints. These
early events create a first level of autoimmune injury,
which is clinically silent but might generate apoptotic
cells and nucleic acid-containing immune complexes.
The capture of these apoptotic cells by mDCs and
nucleic acid-containing ICs by pDCs and autoreactive
B cells broadens the autoimmune reaction, thereby
leading to disease manifestations.
The past 5 years have highlighted the pathogenic role
of IFN-ab and nucleic acid-containing immune com-
plexes in SLE. Research within the next 5 years will
hopefully help us to understand the basic genetic alter-
ations leading to IFN-ab overproduction and B cell tol-
erance breakdown in SLE, thus eventually allowing us
to identify individuals with predisposition; establish
the role of other cells like neutrophils, TFh cells, and
Tr1 cells in the pathogenesis of human SLE, thus even-
tually allowing us to uncover new avenues of treatment;
determine whether, like TNF antagonists, which have
brought considerable relief to RA patients, IFN antago-
nists will bring relief to SLE patients; and apply new
tools, e.g., transcriptome analysis, to diagnose the dis-
ease during its preclinical stage. Inasmuch as SLE often
takes years to develop after the generation of the first
wave of autoantibodies, we foresee with enthusiasm
the day when blocking IFN during the preclinical phase
of SLE might prevent the appearance of clinical symp-
toms and thus avoid the terrible morbidity associated
with this disease.
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